Portfolio — 30 March 2026

The Minister for Health and Ageing, Mr Butler, announced the establishment of a national Prostate Cancer Expert Advisory Group on 31 March, the most significant prostate cancer governance initiative the portfolio has advanced this year. The move extends the portfolio's recent activity in cancer care: on 28 February, expanded PBS listings for immunotherapy drugs were announced, and the advisory group is explicitly framed as the next implementation step under the Australian Cancer Plan, the ten-year national framework for equitable, person-centred cancer care [TA-260331-health-041bc477a38f].

The group will be co-chaired by the Special Envoy for Men's Health, Mr Dan Repacholi MP, and Associate Professor Chris Milross of Cancer Australia. Its brief covers three distinct but connected priorities: early detection targeted at those at highest risk; minimising overdiagnosis and overtreatment; and supporting men and their families through the physical, psychological and financial consequences of the disease [TA-260331-health-041bc477a38f].

The dual-chair structure — pairing a parliamentary envoy with a clinical expert from Cancer Australia — signals the portfolio's intent to bridge advocacy and clinical evidence within the group's governance.

The Minister for Health and Ageing framed the group as a direct response to documented inequities in prostate cancer detection and treatment across the Australian population [TA-260331-health-041bc477a38f]. Prostate cancer is the most commonly diagnosed cancer in Australia and the second leading cause of cancer mortality among men, which gives the equity framing particular policy weight.

The portfolio's stated approach — coordinating clinical expertise, lived experience and evidence — is consistent with the broader Australian Cancer Plan methodology and mirrors the framing used in the February PBS announcement.